|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Cholinesterase, Serum, with Dibucaine Inhibition
Test CodePCHOL
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Transport Container
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 21 days
Refrigerated: 21 days
Frozen: 30 days
Refrigerated: 21 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis
Methodology
Kinetic Spectrophotometric (KS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 1 day
Limitations
Elevated values, caused by the presence of young RBCs and reticulocytes, may mask acetylcholinesterase inhibition.
Clinical Significance
The Pseudocholinesterase phenotype can be determined by analysis of Pseudocholinesterase and the percent inhibition by Dibucaine. Approximately 96% of the population has normal activity, approximately 4% will exhibit decreased activity that leads to prolonged paralysis following use of succinylcholine, and 1 in 3000 patients will exhibit severe, prolonged paralysis following anesthetic exposure.
